This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Earnings Preview: Zoetis (ZTS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Zoetis (ZTS) closed at $176.88, marking a +1.42% move from the previous day.
ALPMY or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALPMY vs. ZTS: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights NIKE, Toyota Motor, ConocoPhillips, PayPal and Zoetis
by Zacks Equity Research
NIKE, Toyota Motor, ConocoPhillips, PayPal and Zoetis are part of the Zacks top Analyst Blog.
Q1 Earnings Scorecard and Analyst Reports for NIKE, Toyota Motor & ConocoPhillips
by Sheraz Mian
Today's Research Daily features Q1 earnings season update and new research reports on NIKE, Inc. (NKE), Toyota (TM) and ConocoPhillips (COP).
Zoetis (ZTS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Zoetis (ZTS) closed at $164.47 in the latest trading session, marking a -1.11% move from the prior day.
The Zacks Analyst Blog Highlights Nike, Salesforce, Zoetis, Archer-Daniels-Midland and Trane Technologies
by Zacks Equity Research
Nike, Salesforce, Zoetis, Archer-Daniels-Midland and Trane Technologies are part of the Zacks top Analyst Blog.
Top Research Reports for Nike, Salesforce & Zoetis
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NIKE, Inc. (NKE), Salesforce, Inc. (CRM) and Zoetis Inc. (ZTS).
Zoetis (ZTS) Down 6.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
COLL vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
Zoetis' (ZTS) Q4 Earnings in Line With Estimates, Revenues Beat
by Zacks Equity Research
Zoetis' (ZTS) fourth-quarter 2022 earnings per share was at par with the Zacks Consensus Estimate, while revenues beat the same. The company provides its financial guidance for 2023.
Zoetis (ZTS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zoetis (ZTS) Matches Q4 Earnings Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 0% and 1.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
COLL or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are expected to have driven sales, partially offset by lower sales of livestock, cattle, poultry and swine products.
Zoetis (ZTS) Stock Moves -0.78%: What You Should Know
by Zacks Equity Research
Zoetis (ZTS) closed the most recent trading day at $160.81, moving -0.78% from the previous trading session.
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Zoetis (ZTS) closed at $171 in the latest trading session, marking a +1.9% move from the prior day.
Zoetis (ZTS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Zoetis (ZTS) closed at $165.18 in the latest trading session, marking a -1.82% move from the prior day.
UTHR vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
UTHR vs. ZTS: Which Stock Is the Better Value Option?
COLL vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
Top Research Reports for Berkshire Hathaway, Walmart, and P&G
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Walmart Inc. (WMT) and The Procter & Gamble Company (PG).
ASRT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
ASRT or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Why Is Ionis Pharmaceuticals (IONS) Down 16.4% Since Last Earnings Report?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.